‍Things You Should Know

What does menopause fundamentally describe?

Menopause describes the permanent end of menstrual periods after ovarian follicular activity has ceased. In clinical use, it is usually confirmed after 12 consecutive months without menstruation. The transition before that point is called perimenopause, and the stage after that point is postmenopause. Research also distinguishes natural menopause from surgical or iatrogenic menopause, which follows removal of the ovaries or medical treatment that stops ovarian function.

This distinction matters because menopause is not a single event with one uniform pattern. Human qualitative and observational studies suggest that hormone levels fluctuate during the transition, rather than simply falling in a straight line. Estrogen and progesterone both change, and these shifts may help explain why symptoms can vary over time. Common terms include final menstrual period (FMP), vasomotor symptoms, and genitourinary changes.

For longevity, menopause is best understood as a life-stage transition rather than a disease. Available human evidence links this stage with changes in bone, cardiovascular, sexual, and psychological health, but symptom burden and health impact differ widely. Scientific literature also shows that social context, stress, and cultural beliefs shape how menopause is experienced and reported.

Why does menopause matter for healthy longevity?

Menopause matters for longevity because it often overlaps with a period when long-term health risks begin to shift. Human cohort studies and clinical frameworks associate the menopausal transition with changes in bone density, cardiovascular risk factors, mood, sleep, and sexual health. These associations do not mean every change is caused only by menopause, since aging, prior health status, and social conditions also contribute.

One common misunderstanding is that estrogen decline directly causes overall weight gain. Available human evidence suggests a more specific pattern: menopause is associated with body fat redistribution, often from a more gynoid pattern toward greater visceral fat accumulation. That pattern may have implications for cardiometabolic health over time. Research frameworks also note that changes in estradiol, follicle-stimulating hormone (FSH), and androgen indices occur alongside broader metabolic and functional changes.

Longevity is not only about lifespan, but also about preserving function. Scientific literature supports viewing healthy menopause as the ability to maintain physical, psychological, and social functioning while adapting to change. That perspective is especially relevant because many women now spend decades in postmenopause, making midlife transitions important for later-life independence and quality of life.

Which core menopause terms are worth knowing?

Several basic terms make menopause easier to understand. Perimenopause is the transitional phase marked by changing ovarian function and often irregular menstrual cycles. Menopause is the final menstrual period, recognized in retrospect after 12 months without bleeding. Postmenopause refers to the years after that point. Premature menopause generally means menopause at an unusually early age, while surgical or iatrogenic menopause refers to menopause caused by surgery or medical treatment rather than natural reproductive aging.

Another useful term is vasomotor symptoms, which includes hot flashes and night sweats. Genitourinary atrophy refers to tissue changes that may affect the vagina, bladder, and urinary tract, sometimes contributing to dryness, discomfort, or urinary symptoms. Dyspareunia means pain during sexual activity. Amenorrhea means absence of menstrual bleeding.

A broader concept from human research is the biopsychosocial model. This means menopause is shaped not only by biology, but also by mood, relationships, culture, work demands, and health literacy. That framework matters for longevity because symptoms, coping, and long-term health outcomes may depend partly on whether women have social support, clear information, and access to care across midlife and beyond.

Who may need this knowledge most?

This knowledge may be especially relevant for women in midlife, usually between the mid-40s and early 50s, but some groups may have a greater need for early awareness. Human studies and conceptual frameworks suggest that women with premature menopause, surgical menopause, or treatment-related menopause often face a more abrupt hormonal change. In those settings, symptoms may be more sudden or intense, and the implications for bone and cardiovascular health may become more pressing at a younger age.

Women with a family history of osteoporosis, low body weight, prolonged corticosteroid use, smoking, or limited access to healthcare may also benefit from better menopause literacy. Available human evidence further suggests that symptom burden and coping can differ by education, marital support, employment, economic status, and cultural attitudes. These are examples of social determinants of health (SDH), meaning the conditions in which people live and work.

The evidence base also shows that menopause is not experienced uniformly across populations. Most findings here come from human qualitative studies, integrative reviews, and health frameworks, which are informative but may be influenced by reporting bias, local culture, and differences in symptom interpretation. That is important when applying menopause knowledge to diverse groups.

When and where is menopause knowledge most relevant?

Menopause knowledge becomes relevant before periods stop completely, often when cycle timing starts to change or when symptoms such as sleep disruption, hot flashes, or vaginal dryness begin to appear. Human studies suggest that uncertainty is common during this stage because symptoms can overlap with general aging, stress, and other life pressures. Early understanding may reduce confusion and help women interpret the transition more accurately.

This knowledge is also highly relevant in certain contexts: after ovary removal, during cancer-related therapy that affects ovarian function, when there is early menopause in the family, or when fracture or cardiometabolic risk is already elevated. It can matter in workplaces, caregiving settings, and intimate relationships because sleep loss, mood changes, and sexual symptoms may affect daily function and social wellbeing.

Research also indicates that menopause should be understood within a social environment, not just a clinical one. Human qualitative studies describe the importance of partner responses, family expectations, and cultural meaning. For healthy longevity, the central principle is timing: the menopausal transition is often a window for noticing changes in function, risk profile, and support needs long before later-life disability becomes evident.

Tell Me More

How does menopause interact with bladder, vaginal, and sexual health?

Available human evidence suggests menopause often overlaps with genitourinary changes, not only hot flashes. Qualitative human studies describe vaginal dryness, urinary problems, and reduced sexual comfort or desire during the transition. A descriptive hospital-based human study also reported urinary frequency, dysuria, urgency, vaginal dryness, and dyspareunia, meaning pain during sexual activity. A conceptual human framework further identifies low desire, poor arousal, reduced lubrication, dyspareunia, and orgasmic difficulty as recognized sexual health concerns after menopause.

A common misconception is that these symptoms are minor or inevitable and therefore not relevant to healthy aging. In practice, they may affect sleep, activity, relationships, and willingness to exercise or stay socially engaged, which can indirectly matter for long-term function. The evidence base here is mainly qualitative studies, descriptive human data, and conceptual frameworks rather than large intervention trials, so it supports recognition of patterns more than firm causal estimates. Another misconception is that low libido is purely psychological. Scientific literature indicates that biological, relational, and social factors can all contribute.

Are urinary symptoms and infections just “normal aging”?

Not entirely. Human qualitative studies show many women struggle to separate menopause from general aging, especially when urinary symptoms, dryness, or discomfort appear gradually. Research findings describe this uncertainty as a recurring theme. Menopause-related tissue changes may contribute to bladder and genital symptoms, but the available evidence in this set does not show that every urinary complaint is caused by menopause alone.

That distinction matters for longevity because normalizing all symptoms may delay attention to potentially modifiable problems and reduce daily function. Qualitative human evidence from Sri Lanka reported that treating menopause as purely natural sometimes led women to ignore symptoms and postpone care-seeking. This does not prove worse long-term outcomes in every group, but it supports the concern that under-recognition may allow preventable issues to persist. The evidence also suggests caution with broad claims about urinary tract infections (UTIs). This source set mentions urinary symptoms and bladder health concerns, but it does not provide strong pooled human data proving menopause itself is the sole driver of recurrent urinary tract infections (UTIs).

What do newer studies suggest about menopause and heart health?

Recent human evidence has strengthened the link between earlier natural menopause and later cardiovascular risk. A large pooled human cohort analysis combined data from 17 studies, including 301,438 women, with more than 6.5 million person-years of follow-up and over 14,000 incident cardiovascular disease events. It used Cox proportional-hazards models adjusted for body mass index (BMI), smoking, education, hypertension, race and ethnicity, and age at follow-up. The main outcome was incident cardiovascular disease, identified by self-report and hospital records where available.

The general interpretation is associative, not strictly causal: earlier menopause was linked with higher cardiovascular risk, while later menopause tended to align with lower risk categories. This matters for longevity because cardiovascular disease remains a major driver of disability and mortality in later life. Still, some outcome measurement relied on self-report, cohort methods varied, and not every subgroup had identical data quality. So the strongest conclusion is that age at menopause can act as a risk marker within a broader profile, rather than a stand-alone predictor.

Do stress, culture, and support really change menopause symptoms?

Yes, and the evidence is mostly observational and qualitative in humans. An integrative review of social determinants of health (SDH) reported that culture, education, marital support, employment, and economic conditions were associated with symptom severity, quality of life, and age at menopause. The review also noted that smoking was associated with earlier menopause, while exercise and stronger social support were associated with fewer depressive symptoms and better coping.

A common misconception is that menopause symptoms are driven only by hormone levels. Scientific literature suggests a broader biopsychosocial pattern: beliefs, stress, family context, and social resources may shape what symptoms are noticed, how severe they feel, and whether women seek help. That does not mean symptoms are “all in the mind.” It means biology and context interact. For longevity, this matters because social strain, poor sleep, lower activity, and untreated distress can accumulate across decades. The limitation is that much of this evidence is cross-sectional or qualitative, so it shows associations and lived experience more clearly than cause and effect.

Level Up

How may menopause reshape cardiovascular aging?

Human evidence suggests menopause may alter cardiovascular aging through several linked pathways, not through one isolated hormone change. Clinical and observational studies in women describe declining endogenous oestrogen alongside higher blood pressure, greater salt sensitivity, increased sympathetic tone, and activation of the renin-angiotensin system (RAS). The measured outcome in this literature is often blood pressure, commonly defined as values above 140/90 millimeters of mercury, as well as later coronary heart disease patterns. These shifts may help explain why vascular risk rises after menopause, although aging itself, body composition, smoking, and prior metabolic health also influence the pattern.

A separate human prospective study examined age at menopause in relation to cardiovascular mortality. Its main outcome was death from cardiovascular disease over follow-up, rather than short-term symptom change. The general finding was that earlier menopause was associated with higher later cardiovascular risk, which supports the idea that reproductive aging can serve as a marker of biological aging. That is relevant to longevity because vascular injury accumulates over decades, often before clinical disease appears.

Mechanistic interpretation remains cautious. Some of the proposed protection before menopause relates to effects of oestrogen on vascular function and atherosclerosis, but timing, baseline risk, and pre-existing vessel disease appear to matter. The scientific literature therefore supports menopause as a transition that may modify cardiovascular trajectories, rather than a single direct cause of heart disease in every woman.

What links menopause to bone and muscle aging?

Human and animal evidence together suggest that menopause may accelerate structural aging of the skeleton, while indirectly affecting muscle function through symptoms and reduced activity. In humans, clinical literature consistently links loss of ovarian function with lower bone density and greater fracture vulnerability over time. The key human outcome is usually bone mineral density or later osteoporotic disease, not simply bone pain. This matters for longevity because fractures can reduce mobility, independence, and later-life resilience.

Part of this story is direct and part is indirect. The direct pathway involves lower oestrogen exposure after menopause, which is associated with changes in bone turnover. The indirect pathway is often overlooked. Human symptom studies describe hot flushes, night sweats, insomnia, fatigue, and general aches during the transition. These symptoms may disrupt exercise routines, sleep quality, and daily movement, which can gradually affect muscle mass, balance, and bone loading. That means the musculoskeletal effect of menopause may extend beyond hormones alone.

Animal studies add mechanistic depth but do not prove identical effects in humans. Rodent and mouse models suggest that reproductive aging interacts with nutrient-sensing pathways such as mammalian target of rapamycin (mTOR), which also regulates growth and cellular aging. These findings are hypothesis-generating for human longevity research. They support biological plausibility, but demonstrated long-term fracture prevention or muscle preservation still depends mainly on human outcome studies rather than animal mechanisms alone.

Can menopause affect sleep, mood, and cognition long-term?

Human evidence suggests the menopausal transition may influence sleep, mood, and cognitive function through overlapping biological and social pathways. Qualitative and descriptive studies report insomnia, night sweats, irritability, poor concentration, memory complaints, fatigue, and emotional strain. A conceptual framework for healthy menopause also identifies mood and cognitive functioning as core domains, which reflects their relevance to daily function rather than proving a single disease mechanism.

For longevity, the indirect pathway may be especially important. Poor sleep can reduce physical activity, increase daytime fatigue, and impair regular routines that support metabolic and cardiovascular health. Repeated vasomotor symptoms, especially at night, may fragment sleep and lower recovery. Mood symptoms may also alter social engagement and self-management. These are not trivial quality-of-life issues. Over years, they may influence functional aging, even when they do not map neatly onto a specific diagnosis.

The evidence base has limits. Much of the symptom literature is observational or qualitative in humans, so it is better at showing patterns of lived experience than proving causation. Reports of memory change, for example, may reflect sleep loss, stress, aging, or menopause-related hormonal change in varying proportions. The most balanced interpretation is that menopause may contribute to a cluster of sleep and neuropsychological changes, and those changes may matter for healthy longevity by shaping behavior, adaptation, and long-term function.

Which advanced theories may change future menopause care?

Several advanced theories may influence how menopause is understood over the next decade, especially in longevity research. One is the quasi-program concept, proposed mainly from evolutionary and mechanistic scholarship. In this model, menopause is not viewed only as passive ovarian exhaustion. It may reflect the continued action of biological programs that were useful earlier in life but become dysregulated later. Related work points to mammalian target of rapamycin (mTOR) as a nutrient-sensing pathway that supports growth and reproduction early on, yet is also linked to cellular senescence and age-related disease.

Support for this theory comes mostly from mechanistic reasoning and in vivo animal studies. Mouse studies with altered phosphatase and tensin homolog (PTEN) or tuberous sclerosis complex 1 (Tsc1) signaling show accelerated follicle activation and premature ovarian failure when mTOR activity is excessive. These findings are biologically informative, but they do not establish that targeting this pathway will safely delay menopause or extend healthy lifespan in humans.

A second theory is evolutionary rather than molecular. It proposes that menopause emerged because late reproduction became too energetically costly when offspring required prolonged care. This idea helps frame menopause as part of life-history strategy, not merely endocrine decline. For future care, these theories may shift attention toward biological aging pace, timing of reproductive aging, and the interaction between ovarian aging and whole-body aging. At present, however, human outcome evidence remains more limited than the theories themselves.

Pros and Cons

Pros

• Adapts healthy menopause
  ‍Conceptual human frameworks describe menopause literacy and individualized support as linked to better self-management, functioning, and quality of life across physical, psychological, and social domains.

• Supports symptom coping
  ‍Observational and qualitative human studies associate exercise, social support, and better menopause knowledge with lower symptom burden, fewer depressive symptoms, and improved day-to-day coping in midlife.

• Highlights hidden domains
  ‍A broad menopause view brings attention beyond hot flashes to sleep, mood, musculoskeletal discomfort, urogenital symptoms, and sexual health, which may help preserve function over time.

• Improves risk awareness
  ‍Human cohort and framework evidence links menopause timing and transition-related changes with bone and cardiovascular risk patterns. Awareness may support earlier recognition of later-life health vulnerability.

• May strengthen support
  ‍Qualitative and integrative human evidence suggests partner, family, and peer understanding is associated with less distress and better quality of life, with indirect benefits for resilience and social functioning.

Cons

• Bone loss risk rises
  ‍Human clinical and framework evidence associates late perimenopause and early postmenopause with accelerated bone loss, which may increase later osteoporosis and fracture vulnerability relevant to longevity.

• Cardiovascular risk shifts
  ‍Human cohort and conceptual evidence suggests menopause, especially when earlier, is associated with less favorable lipid and vascular risk patterns. Risk is shaped by aging, smoking, and prior health status too.

• Mood and cognition strain
  ‍Human observational and qualitative studies report more depressive symptoms, poor concentration, memory complaints, fatigue, and sleep disruption during the transition, which may impair daily function.

• Urogenital and sexual burden
  ‍Human qualitative and conceptual evidence links menopause with vaginal dryness, urinary symptoms, dyspareunia, lower desire, and reduced lubrication. These effects may affect intimacy, sleep, and activity.

• Naturalizing may delay care
  ‍Qualitative human studies suggest that viewing menopause as something to simply endure may delay evaluation of heavy bleeding, anemia, cancer warning signs, or other modifiable health problems.

Considerations

• Perimenopause is fertile
  ‍Perimenopause does not mean fertility is absent. Pregnancy can still occur until menopause is confirmed after 12 months without menstruation, so this transition should not be treated as immediate infertility.

• Symptoms vary by context
  ‍Human observational and qualitative evidence suggests symptom patterns differ by culture, education, stress, marital support, employment, and economic conditions. One experience should not define all women.

• Not all symptoms are menopause
  ‍Available evidence suggests overlap with aging, stress, and other health conditions. Urinary, cognitive, bleeding, or pain symptoms may not be explained by menopause alone and may need separate assessment.

• Special groups differ
  ‍Premature, surgical, and treatment-related menopause may involve more abrupt changes and earlier long-term risk exposure than natural menopause, so evidence from natural menopause may not fully generalize.

• Comorbidities matter
  ‍Fibroids, endometriosis, and PMDD can still shape bleeding, pain, and mood patterns during the transition. Research and care models do not always separate these effects cleanly from menopause itself.

Actionable Intelligence

Innovative Tips

• Symptom Mapping Sprint
  ‍Human obs.: track hot flashes, sleep, mood daily for 14 days; patterns may emerge early.
  ‍
• Night Heat Pattern Log
  ‍Human obs.: log sweats, wake time, fatigue for 2 weeks; sleep links remain exploratory.
  ‍
• Micro-Strength Blocks
  ‍Human framework: 10-15 min bands 3x weekly for 8 weeks may support bone loading.
  ‍
• Partner Check-In Trial
  ‍Human qualitative: 1 weekly talk for 6 weeks may support coping; effects vary by context.
  ‍
• Phytoestrogen Food Notes
  ‍Human observational: note soy or legumes most days for 2 weeks; benefit is not established.
  ‍
• Mood-Support Mapping
  ‍Human qualitative: log stress, support, mood weekly for 6 weeks; context may shape symptoms.
  ‍
• Movement-Symptom Pairing
  ‍Human obs.: pair 20-min walks with symptom logs for 4 weeks; changes may be modest.
  ‍
• Menopause Age Flag
  ‍Human cohort: record menopause age once; earlier timing may mark later heart risk.
  ‍
• Social Buffer Experiment
  ‍Human review: add 1 peer contact weekly for 6 weeks; quality-of-life gains are associative.
  ‍
• Cultural Coping Journal
  ‍Qualitative human data: journal beliefs and symptoms weekly for 1 month; bias may matter.

Convergent and Divergent Viewpoints

Convergents

• Menopause is a life-stage transition, not a disease state
  ‍Human qualitative and conceptual evidence consistently frames menopause as natural reproductive aging. Longevity relevance centers on preserving function across decades of postmenopausal life, not treating menopause itself as pathology.

• Health effects are multidomain and extend beyond hot flashes
  ‍Human studies and frameworks agree menopause may affect physical, psychological, sexual, urinary, sleep, and social domains. Longevity depends on these domains because function, mobility, and daily resilience interact over time.

• Bone vulnerability rises after ovarian function declines
  ‍Human clinical and conceptual evidence consistently links postmenopause with faster bone loss and higher fracture vulnerability. This is a strong longevity concern because fractures may reduce mobility, independence, and later-life reserve.

• Cardiovascular risk generally shifts upward after menopause
  ‍Human cohort and framework evidence supports menopause as a period of less favorable vascular risk, especially when menopause occurs earlier. It is best treated as a risk marker within broader aging and lifestyle context.

• Social context materially shapes symptom burden and coping
  ‍Human observational, review, and qualitative evidence agrees that education, support, culture, work, and finances influence symptom reporting, distress, and care-seeking. This matters for longevity through behavior and access pathways.

• Symptom variability is expected rather than exceptional
  ‍Human qualitative and observational studies consistently report wide variation in onset, duration, and type of symptoms. Available evidence does not support one universal menopause pattern across all women or populations.

• Normalizing symptoms can delay attention to modifiable problems
  ‍Human qualitative evidence agrees that seeing menopause as something to simply endure may delay help-seeking. Longevity relevance is indirect but important, since persistent bleeding, anemia, pain, or urinary issues may be overlooked.

• Support and health literacy may improve adaptation
  ‍Human qualitative studies, integrative review findings, and conceptual frameworks align that better information and family or peer support are associated with improved coping and quality of life, though causality remains limited.

Divergent

• How much symptoms reflect menopause itself versus midlife context
  ‍Some researchers argue hormone change explains most midlife symptoms; others argue aging, stress, and life circumstances explain a large share. The debate persists because many studies are observational or qualitative rather than causal.

• Whether symptom frequency differs mainly by biology or by reporting culture
  ‍Some say cross-cultural symptom differences reflect biology or diet; others say meaning, language, and reporting norms drive much of the variation. This affects how broadly prevalence findings can be generalized.

• How strongly menopause timing should weigh in heart-risk prediction
  ‍Some researchers treat earlier menopause as a meaningful cardiovascular risk marker; others view it as one modest factor among smoking, blood pressure, diabetes, and adiposity. The divide is mainly about predictive weight, not existence of association.

• Whether menopause should be assessed mainly by symptoms or by broader function
  ‍Some say vasomotor and cycle changes should anchor assessment; others argue physical, psychological, social, and sexual functioning should carry equal weight. This debate matters for what outcomes count in healthy longevity.

• How useful conceptual models are for guiding real-world menopause care
  ‍Some researchers favor broad woman-centered frameworks to capture adaptation and resilience; others argue they are hard to measure consistently and less actionable than standard symptom or disease endpoints.

• Whether positive attitudes reduce symptoms or mainly change interpretation
  ‍Some say a positive view of aging and menopause may lessen symptom burden; others say it mostly alters appraisal and reporting, not biology. Evidence is limited by cross-sectional designs and cultural confounding.

• How far lifestyle associations can be interpreted as intervention effects
  ‍Some researchers infer exercise, diet, and support may reduce symptom burden; others caution that healthier women may simply report better outcomes. The disagreement reflects limited trial data and likely confounding.

• Where to place mechanistic aging theories in present menopause science
  ‍Some say pathways such as mTOR may reshape menopause longevity research; others say human outcome evidence is too early for these theories to guide interpretation. The divide is between plausibility and demonstrated human benefit.

Longevity Index

70/100

Definition

• Amenorrhea
  ‍Absence of menstrual bleeding.

• Androgen indices
  ‍Measures that reflect levels or activity of androgens, a group of sex hormones that includes testosterone.

• Arousal
  ‍In sexual health, the state of becoming physically and mentally sexually responsive.

• Atherosclerosis
  ‍A process in which fatty deposits and other material build up in artery walls, which can reduce blood flow and raise cardiovascular risk.

• Biopsychosocial model
  ‍A broader concept from human research is the biopsychosocial model. This means menopause is shaped not only by biology, but also by mood, relationships, culture, work demands, and health literacy.

• Blood pressure above 140/90 millimeters of mercury
  ‍A commonly used threshold in the cited literature for elevated blood pressure.

• Body mass index (BMI)
  ‍A weight-for-height measure commonly used in health research to help classify body size.

• Bone mineral density
  ‍The amount of mineral in bone, used as a key measure of bone strength and fracture risk.

• Cardiometabolic health
  ‍Health related to the heart, blood vessels, metabolism, and conditions such as diabetes and obesity.

• Cardiovascular disease
  ‍A group of disorders involving the heart and blood vessels.

• Cardiovascular mortality
  ‍Death caused by cardiovascular disease.

• Causal
  ‍Showing that one factor directly produces an effect, rather than just being associated with it.

• Cognition
  ‍Mental processes such as attention, memory, and thinking.

• Cohort analysis
  ‍A research approach that follows groups of people over time to examine how exposures or characteristics relate to later outcomes.

• Cox proportional-hazards models
  ‍A statistical method used in cohort studies to estimate how a factor is associated with the rate of an outcome over time, while adjusting for other variables.

• Cross-sectional
  ‍A study design that looks at a population at one point in time, which can show associations but is limited for proving cause and effect.

• Cultural confounding
  ‍A situation in which cultural differences may influence study findings, making it harder to isolate the role of biology or another factor.

• Descriptive hospital-based human study
  ‍A study done in people in a hospital setting that mainly describes symptom patterns or characteristics rather than testing a treatment.

• Dysuria
  ‍Pain or discomfort during urination.

• Dyspareunia
  ‍Dyspareunia means pain during sexual activity.

• Education as a social determinant
  ‍Part of social determinants of health; level of education may influence menopause knowledge, coping, symptom reporting, and access to care.

• Endogenous oestrogen
  ‍Oestrogen produced naturally by the body.

• Endometriosis
  ‍A condition in which tissue similar to the uterine lining grows outside the uterus and can contribute to pain and bleeding symptoms.

• Estradiol
  ‍A main form of estrogen measured in reproductive and menopause research.

• Estrogen
  ‍A group of sex hormones involved in reproductive function, bone health, and many other body systems.

• Evolutionary theory of menopause
  ‍A theory proposing that menopause emerged because late reproduction became too energetically costly when offspring required prolonged care.

• Final menstrual period (FMP)
  ‍The last menstrual period, recognized in retrospect after 12 months without menstruation.

• Follicle-stimulating hormone (FSH)
• ‍A hormone involved in regulating ovarian function that often changes during the menopausal transition.

• Fracture vulnerability
  ‍Increased likelihood of breaking a bone.

• Functional aging
  ‍Changes over time in a person’s ability to carry out physical, psychological, and social functions.

• Genitourinary atrophy
  ‍Genitourinary atrophy refers to tissue changes that may affect the vagina, bladder, and urinary tract, sometimes contributing to dryness, discomfort, or urinary symptoms.

• Genitourinary changes
  ‍Changes affecting the genital and urinary systems, such as vaginal dryness, urinary symptoms, or tissue changes.

• Genital symptoms
  ‍Symptoms affecting the reproductive or external genital tissues, such as dryness or discomfort.

• Gynoid fat pattern
  ‍A body fat distribution pattern in which fat is stored more around the hips and thighs.

• Health literacy
  ‍The ability to obtain, understand, and use health information.

• Hot flashes
  ‍Sudden feelings of heat, often with sweating and flushing, that are part of vasomotor symptoms.

• Hypertension
  ‍High blood pressure.

• Incident cardiovascular disease
  ‍New cases of cardiovascular disease that occur during study follow-up.

• In integrative reviews
  ‍Reviews that combine findings from different types of studies to provide a broader understanding of a topic.

• Insomnia
  ‍Difficulty falling asleep, staying asleep, or getting restorative sleep.

• Iatrogenic menopause
  ‍Research also distinguishes natural menopause from surgical or iatrogenic menopause, which follows removal of the ovaries or medical treatment that stops ovarian function.

• In vivo animal studies
  ‍Research performed in living animals rather than in isolated cells or tissues.

• Lubrication
  ‍In sexual health, the production of moisture that helps make sexual activity more comfortable.

• mammalian target of rapamycin (mTOR)
  ‍A nutrient-sensing pathway that supports growth and reproduction early on, yet is also linked to cellular senescence and age-related disease.

• Mechanistic interpretation
  ‍An explanation focused on the biological processes that might produce an observed effect.

• Menopause
  ‍Menopause describes the permanent end of menstrual periods after ovarian follicular activity has ceased. In clinical use, it is usually confirmed after 12 consecutive months without menstruation.

• Menopause literacy
  ‍Knowledge and understanding that help a person recognize, interpret, and manage menopause-related changes.

• Metabolic health
  ‍Health related to energy use and storage, including blood sugar, lipids, and body composition.

• Mood symptoms
  ‍Emotional changes such as irritability, depressive symptoms, anxiety, or emotional strain.

• Natural menopause
  ‍Menopause that occurs through natural reproductive aging rather than surgery or medical treatment.

• Night sweats
  ‍Episodes of excessive sweating during sleep, commonly included within vasomotor symptoms.

• Observational studies
  ‍Studies that observe people and measure associations without assigning an intervention.

• Oestrogen
  ‍A British spelling of estrogen; a group of sex hormones involved in reproductive and broader body functions.

• Oophorectomy or ovary removal
  ‍Surgical removal of the ovaries, which can lead to abrupt menopause.

• Orgasmic difficulty
  ‍Trouble reaching orgasm.

• Osteoporosis
  ‍A disease of low bone strength that increases fracture risk.

• Ovarian follicular activity
  ‍The normal activity of follicles in the ovaries, which support ovulation and hormone production.

• Ovarian function
  ‍The ovaries’ role in producing eggs and hormones such as estrogen and progesterone.

• Perimenopause
  ‍Perimenopause is the transitional phase marked by changing ovarian function and often irregular menstrual cycles.

• Person-years of follow-up
  ‍A measure used in long-term studies that combines the number of people and the amount of time each person is followed.

• Phosphatase and tensin homolog (PTEN)
  ‍A gene and signaling regulator studied in animal models; altered PTEN signaling has been linked to accelerated follicle activation in mechanistic menopause research.

• Phytoestrogens
  ‍Plant compounds that act a bit like estrogen.

• Pooled cohort analysis
  ‍An analysis that combines data from multiple cohort studies to increase sample size and statistical power.

• Postmenopause
  ‍Postmenopause refers to the years after that point.

• Premature menopause
  ‍Premature menopause generally means menopause at an unusually early age.

• Premature ovarian failure
  ‍An early loss of normal ovarian function.

• Progesterone
  ‍A sex hormone involved in menstrual cycling and reproductive function.

• Proatherogenic lipid changes
  ‍Changes in blood fats that may promote atherosclerosis and increase cardiovascular risk.

• Prospective study
  ‍A study that follows participants forward in time to assess later outcomes.

• Qualitative studies
  ‍Studies that explore people’s experiences, meanings, and perceptions, often through interviews or narratives.

• Quasi-program concept
  ‍In this model, menopause is not viewed only as passive ovarian exhaustion. It may reflect the continued action of biological programs that were useful earlier in life but become dysregulated later.

• Race and ethnicity adjustment
  ‍In statistical analysis, accounting for race and ethnicity so they do not distort the estimated association between the main exposure and outcome.

• Renin-angiotensin system (RAS)
  ‍A hormone system involved in blood pressure regulation and fluid balance.

• Reproductive aging
  ‍The aging-related changes in reproductive function, including ovarian aging and menopause timing.

• Salt sensitivity
  ‍A tendency for blood pressure to respond strongly to salt intake.

• Scientific literature
  ‍Published research evidence and scholarly analysis on a topic.

• Self-report
  ‍Information provided directly by study participants about their symptoms, diagnoses, or experiences.

• Senescence
  ‍A biological state in which cells stop dividing normally and may contribute to aging-related dysfunction.

• Sexual functioning
  ‍A broad domain that includes desire, arousal, lubrication, comfort, and orgasm.

• Social determinants of health (SDH)
  ‍These are examples of social determinants of health (SDH), meaning the conditions in which people live and work.

• Statistical power
  ‍The ability of a study to detect an association if one truly exists.

• Surgical menopause
  ‍Surgical or iatrogenic menopause refers to menopause caused by surgery or medical treatment rather than natural reproductive aging.

• Sympathetic tone
  ‍The level of activity in the sympathetic nervous system, which can influence heart rate and blood pressure.

• Tissue changes
  ‍Physical changes in body tissues, such as thinning or drying of vaginal or urinary tissues after menopause.

• Treatment-related menopause
  ‍Menopause caused by medical therapies, such as cancer treatment, that affect ovarian function.

• Tsc1 (tuberous sclerosis complex 1)
  ‍A gene involved in cell-growth signaling; altered Tsc1 signaling in mouse studies has been linked to accelerated follicle activation through the mTOR pathway.

• Urgency
  ‍A sudden, hard-to-delay need to urinate.

• Urinary frequency
  ‍Needing to urinate more often than usual.

• Urinary tract infections (UTIs)
  Infections affecting parts of the urinary tract, such as the bladder or urethra.

• Urogenital symptoms
  ‍Symptoms involving the urinary and genital systems, such as dryness, discomfort, or urinary complaints.

• Vaginal dryness
  ‍Reduced vaginal moisture that may cause discomfort, irritation, or pain during sexual activity.

• Vascular function
  ‍How well blood vessels work, including their ability to regulate blood flow and pressure.

• Vascular injury
  ‍Damage that builds up in blood vessels over time.

• Vasomotor symptoms
  ‍Another useful term is vasomotor symptoms, which includes hot flashes and night sweats.

• Visceral fat accumulation
  ‍A pattern of body fat storage deeper in the abdomen, around internal organs, with implications for cardiometabolic health.

‍